EVIDENCE-BASED RECOMMENDATIONS FOR THE CLINICAL USE OF RECOMBINANT-HUMAN-ERYTHROPOIETIN

被引：80

作者：

MUIRHEAD, N

BARGMAN, J

BURGESS, E

JINDAL, KK

LEVIN, A

NOLIN, L

PARFREY, P

机构：

[1] UNIV WESTERN ONTARIO, DEPT MED, LONDON, ON, CANADA

[2] UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA

[3] UNIV TORONTO, TORONTO GEN HOSP, TORONTO, ON M5G 1L7, CANADA

[4] UNIV CALGARY, CALGARY, AB, CANADA

[5] FOOTHILLS PROV GEN HOSP, CALGARY, AB, CANADA

[6] DALHOUSIE UNIV, DEPT MED, DIV NEPHROL, HALIFAX, NS, CANADA

[7] VICTORIA GEN HOSP, HALIFAX, NS B3H 2Y9, CANADA

[8] UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER, BC, CANADA

[9] ST PAULS HOSP, VANCOUVER, BC V6Z 1Y6, CANADA

[10] HOP MAISON NEUVE ROSEMONT, DEPT MED, MONTREAL, PQ H1T 2M4, CANADA

[11] MEM UNIV NEWFOUNDLAND, DEPT MED, St John, NF, CANADA

[12] HLTH SCI CTR, St John, NF, CANADA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 1995年 / 26卷 / 02期

关键词：

KIDNEY FAILURE; CHRONIC; HEMODIALYSIS; PERITONEAL DIALYSIS; ANEMIA; ERYTHROPOIETIN; RHUEPO; GUIDELINES;

D O I：

10.1016/0272-6386(95)90645-2

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

In an era of increasing scrutiny regarding use of health care resources, it is critical that physicians have rational, evidence-based guidelines for treatment decisions. This review of more than 200 published papers constitutes a comprehensive approach to evaluating the current evidence regarding the clinical use of recombinant human erythropoietin therapy in renal failure patients. After this review, specific recommendations are provided regarding who should receive r-HuEPO; what the target hemoglobin should be; the best route of administration of r-HuEPO; how iron status should be evaluated and managed; and monitoring and follow-up of patients taking r-HuEPO, Throughout the article, areas for important future research are also identified. (C) 1995 by the National Kidney Foundation, Inc.

引用

页码：S1 / S24

页数：24

共 204 条

[1]

ABELS R, 1990, SEMIN NEPHROL, V10, P20

[2] RENAL-FUNCTION DURING ERYTHROPOIETIN THERAPY FOR ANEMIA IN PREDIALYSIS CHRONIC-RENAL-FAILURE PATIENTS [J].